Free Trial

BioCryst Pharmaceuticals (BCRX) Earnings Date, Estimates & Call Transcripts

BioCryst Pharmaceuticals logo
$7.57 +0.18 (+2.44%)
(As of 12/20/2024 05:51 PM ET)

BioCryst Pharmaceuticals Latest Earnings Summary

Actual EPS
(Nov. 4)
-$0.07
Consensus EPS
(Nov. 4)
-$0.07

BioCryst Pharmaceuticals released Q3 2024 earnings on November 4, 2024, reporting an EPS of -$0.07, which hit the consensus estimate of -$0.07. Quarterly revenue rose 35.1% year-over-year to $117.10 million, above analysts' expectations of $113.99 million. With a trailing EPS of -$0.61, BioCryst Pharmaceuticals' earnings are expected to grow next year, from ($0.38) to ($0.06) per share.

Get BioCryst Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioCryst Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

BCRX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

BCRX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

BioCryst Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241-$0.19-$0.19-$0.19
Q2 20241-$0.14-$0.14-$0.14
Q3 20241-$0.03-$0.03-$0.03
Q4 20241-$0.01-$0.01-$0.01
FY 20244($0.37)($0.37)($0.37)

BioCryst Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
11/4/2024Q3 2024-$0.07-$0.07--$0.07$113.99M$117.10M
8/5/2024Q2 2024-$0.17-$0.06+$0.11-$0.06$98.30M$109.30M
5/6/2024Q1 2024-$0.23-$0.17+$0.06-$0.17$85.62M$92.80M
2/26/2024Q4 2023-$0.24-$0.28 -$0.04-$0.25$89.19M$93.40M
11/2/2023Q3 2023-$0.25-$0.19+$0.06-$0.19$86.54M$86.74M
8/3/2023Q2 2023-$0.25-$0.24+$0.01-$0.08$81.42M$81.01M
Cackling Kamala hates this company (Ad)

Do you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution.

Before that happens, you need to see the details here.
5/3/2023Q1 2023-$0.30-$0.28+$0.02-$0.28$71.44M$68.80M
2/21/2023Q4 2022-$0.19-$0.38 -$0.19-$0.38$74.18M$79.50M

BioCryst Pharmaceuticals Earnings - Frequently Asked Questions

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earning data on Monday, November 4, 2024. Learn more on BCRX's earnings history.

In the previous quarter, BioCryst Pharmaceuticals (NASDAQ:BCRX) reported ($0.07) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.07). Learn more on analysts' earnings estimate vs. BCRX's actual earnings.

The conference call for BioCryst Pharmaceuticals's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for BioCryst Pharmaceuticals's latest earnings report can be read online.
Read Transcript

BioCryst Pharmaceuticals (NASDAQ:BCRX) has a recorded annual revenue of $412.58 million.

BioCryst Pharmaceuticals (NASDAQ:BCRX) has a recorded net income of -$226.54 million. BCRX has generated -$0.61 earnings per share over the last four quarters.

BioCryst Pharmaceuticals's earnings are expected to grow from ($0.38) per share to ($0.06) per share in the next year.

More Earnings Resources from MarketBeat



This page (NASDAQ:BCRX) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners